Stock Traders Purchase Large Volume of Put Options on Bausch Health Cos (NYSE:BHC)

Bausch Health Cos Inc. (NYSE:BHC) was the recipient of some unusual options trading activity on Friday. Stock investors acquired 10,041 put options on the company. This is an increase of 275% compared to the average daily volume of 2,677 put options.

Insiders Place Their Bets

In related news, Director John Paulson purchased 34,721,118 shares of Bausch Health Cos stock in a transaction on Thursday, August 14th. The stock was purchased at an average cost of $9.00 per share, with a total value of $312,490,062.00. Following the acquisition, the director directly owned 70,755,869 shares in the company, valued at approximately $636,802,821. This trade represents a 96.35% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Over the last ninety days, insiders have acquired 37,964,167 shares of company stock valued at $333,757,793. 19.97% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of BHC. Nomura Holdings Inc. grew its holdings in shares of Bausch Health Cos by 106.2% during the first quarter. Nomura Holdings Inc. now owns 23,395,000 shares of the company’s stock worth $151,366,000 after purchasing an additional 12,050,000 shares in the last quarter. Paulson & CO. Inc. boosted its stake in Bausch Health Cos by 24.0% in the second quarter. Paulson & CO. Inc. now owns 32,791,702 shares of the company’s stock worth $218,393,000 after buying an additional 6,352,667 shares in the last quarter. Goldentree Asset Management LP boosted its stake in Bausch Health Cos by 13.2% in the second quarter. Goldentree Asset Management LP now owns 34,254,889 shares of the company’s stock worth $227,848,000 after buying an additional 4,004,889 shares in the last quarter. MUFG Securities EMEA plc purchased a new stake in Bausch Health Cos in the second quarter worth approximately $22,644,000. Finally, SG Americas Securities LLC boosted its stake in Bausch Health Cos by 114.4% in the second quarter. SG Americas Securities LLC now owns 6,152,986 shares of the company’s stock worth $40,979,000 after buying an additional 3,282,684 shares in the last quarter. Hedge funds and other institutional investors own 78.65% of the company’s stock.

Bausch Health Cos Trading Up 0.7%

Shares of BHC stock opened at $6.06 on Friday. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 141.90. The company has a market capitalization of $2.25 billion, a P/E ratio of 23.29 and a beta of 0.43. Bausch Health Cos has a 12-month low of $4.25 and a 12-month high of $9.85. The firm has a 50-day moving average price of $6.94 and a 200 day moving average price of $6.01.

Bausch Health Cos (NYSE:BHC) last posted its earnings results on Wednesday, July 30th. The company reported $0.90 earnings per share for the quarter, missing analysts’ consensus estimates of $0.97 by ($0.07). The company had revenue of $2.57 billion for the quarter, compared to analysts’ expectations of $2.47 billion. Bausch Health Cos had a net margin of 0.99% and a negative return on equity of 852.36%. Bausch Health Cos has set its FY 2025 guidance at EPS. Research analysts forecast that Bausch Health Cos will post 4.41 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently commented on BHC shares. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Bausch Health Cos in a report on Wednesday, October 8th. Wall Street Zen downgraded shares of Bausch Health Cos from a “strong-buy” rating to a “buy” rating in a report on Saturday, October 11th. Three equities research analysts have rated the stock with a Hold rating, According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $9.00.

Bausch Health Cos Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.